Funding

Keiretsu Forum Midwest has completed due diligence and will serve as lead investor for VITRUVIAE’s current bridge funding round. Proceeds raised will fund the development of lead product VIT-GLT, a pan-tumor and pan-viral targeting therapeutic molecule. Activity milestones include formulation development, CMC processes ready for GMP, pharmacokinetics and safety studies, in vivo proof-of-concept by intended route of clinical delivery with well established animal models, and completion of pre-IND meetings with the FDA. Round is expected to close by February 5th.

Inquiries can be directed to info@vitruviae.com